Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus perindopril for post-AMI HFrEF ventricular remodeling
ChiCTR1900023326Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan and perindopril in heart failure with reduced ejection fraction (HFrEF) and myocardial infarction (MI) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Left ventricular ejection fraction, Left ventricular volume and 2 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
sacubitril + valsartanperindopril
03
Conditions
heart failure with reduced ejection fraction (HFrEF)myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR1900023326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023326.